Brind.

Ideaya Biosciences and Hengrui Pharmaceuticals presented data on IDE849, with Hengrui conducting a Phase 1 trial in China.

1 report, 1 independent Updated Jul 23

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Ideaya Biosciences (United States)China

Keep exploring

The entities involved

Ideaya Biosciences (United States)
company in South San Francisco, United States
- Servier and Ideaya Biosciences entered an exclusive license agreement on September 2, 2025.Fri 11:35
China
cultural region, ancient civilization, and nation in East Asia; mostly refers to the People's Republic of China in political situation and rarely refers to the Republic of China
- The European Central Bank is forced to raise interest rates due to energy price shocks from the Iran war and an influx of Chinese exports.Mon 17:49
- The Middle Corridor, linking Central Asia and Europe, is gaining significance in regional trade and energy routes.Mon 17:06

Coverage

Newest first; wire copies grouped

Jul 23PR NewswireIDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer for IDE849 (SHR-4849), a Potential First-in-Class DLL3-TOP1 ADC Clinical effica